Jpmorgan Chase & CO Contrafect Corp Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
SELL
$0.18 - $3.51 $450 - $8,775
-2,500 Reduced 33.21%
5,027 $1,000
Q4 2021

Feb 10, 2022
BUY
$2.47 - $4.14 $6,175 - $10,350
2,500 Added 49.73%
7,527 $20,000
Q3 2021

Nov 12, 2021
BUY
$3.19 - $4.43 $16,036 - $22,269
5,027 New
5,027 $20,000

Others Institutions Holding CFRX

# of Institutions
2
Shares Held
49.2K
Call Options Held
0
Put Options Held
0
View Full List

About CONTRAFECT Corp

CFRX Quotes by TradingView
  • Ticker CFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,332,700
  • Market Cap $1.18M
  • Description
  • ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...
More about CFRX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email